Exelixis and GlaxoSmithKline say they're hitting the gas on their program to develop XL880 as a "leading" MET inhibitor for cancer. Exelixis will review the therapy before proof-of-concept, accelerating Glaxo's decision on whether or not it will accept XL880 for further development and commercialization.
"We are extremely pleased that GSK has asked us to expedite its review process for XL880. This request reflects the high level of excitement around both the compound and the therapeutic potential of MET inhibition," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Our recently reported data from the XL880 Phase 1 trial at the 2007 ASCO Annual Meeting underscore our belief that XL880 is the most advanced MET inhibitor in clinical development, and we and GSK are committed to building upon this leadership position."
- see the release from GSK
Related Articles:
Adverse events force delay in Exelixis trial. Report
Exelixis to collaborate with Genentech. Report
Exelixis signs $157M deal to license hormone receptor. Report